Bhavna Chohan, MSc, PhD

Clinical Assistant Professor, Global Health

Senior Research Scientist, KEMRI, Nairobi, Kenya

Dr. Bhavna Chohan, MSc, PhD, received her Ph.D. (Virology) from University of Washington and MSc (Applied Molecular Biology of Infectious Diseases) from London School of Hygiene & Tropical Medicine, United Kingdom. She has been actively involved with HIV/STI research since 1993, serving as Research Laboratory Manager for collaborative research projects with Universities of Washington and Nairobi in Mombasa, Kenya. After her graduate studies from the University of Washington under the mentorship of Dr. Julie Overbaugh, she returned to Nairobi, Kenya in 2007, where she helped establish a molecular virology research laboratory. Her broad goals are to establish and implement quality research on HIV transmission studies to improve health outcomes in Kenya and build a resource of well-trained and qualified scientists in the country.

Currently, Dr.Chohan serves as the Laboratory Director for the Universities of Nairobi/Washington collaborative research studies in Nairobi and also conducts funded research studies as the lead investigator for the NIH as well as local (Kenya) funded studies. She holds the position of Senior Research Scientist position at Kenya Medical Research Institute (KEMRI) and visiting scientist at the University of Nairobi. She provides lectures and mentors students and junior scientists at KEMRI. Her research interests have been focused on HIV transmission and drug resistance studies.

Publications

  1. Koss, CA, Gandhi, M, Halvas, EK, Okochi, H, Chu, C, Glidden, DV et al.. First Case of HIV Seroconversion With Integrase Resistance Mutations on Long-Acting Cabotegravir for Prevention in Routine Care. Open Forum Infect Dis. 2024;11 (9):ofae468. doi: 10.1093/ofid/ofae468. PubMed PMID:39229286 PubMed Central PMC11370791.
  2. Maqsood, R, Holland, LA, Wu, LI, Begnel, ER, Adhiambo, J, Owiti, P et al.. Gut virome and microbiome dynamics before and after SARS-CoV-2 infection in women living with HIV and their infants. Gut Microbes. 2024;16 (1):2394248. doi: 10.1080/19490976.2024.2394248. PubMed PMID:39185682 PubMed Central PMC11352790.
  3. MacLean, F, Tsegaye, AT, Graham, JB, Swarts, JL, Vick, SC, Potchen, N et al.. Bacterial vaginosis-driven changes in vaginal T cell phenotypes and their implications for HIV susceptibility. bioRxiv. 2024; :. doi: 10.1101/2024.07.03.601916. PubMed PMID:39005354 PubMed Central PMC11245000.
  4. Giang, JH, Basha, G, Thomas, KK, Oyaro, P, Chohan, BH, Kingwara, L et al.. Real-world performance of point-of-care vs. standard-of-care HIV viral load testing in western Kenya: Secondary analysis of Opt4Kids and Opt4Mamas studies. PLOS Glob Public Health. 2024;4 (6):e0003378. doi: 10.1371/journal.pgph.0003378. PubMed PMID:38913630 PubMed Central PMC11195974.
  5. Žuštra, A, Leonard, VR, Holland, LA, Hu, JC, Mu, T, Holland, SC et al.. Longitudinal dynamics of the nasopharyngal microbiome in response to SARS-CoV-2 Omicron variant and HIV infection in Kenyan women and their infants. Res Sq. 2024; :. doi: 10.21203/rs.3.rs-4257641/v1. PubMed PMID:38699359 PubMed Central PMC11065085.
Search PubMed

Comments are closed.